bold = Main text
Part, Chapter, Paragraphgrey = Comment text
5501 II, 9. 5. 3 | extracurricular activities can have a male-sport bias. Activities are often
5502 II, 9. 1. 2 | the proportion of multiply malformed cases where a karyotype
5503 II, 9. 5. 3 | younger, they may also be more malleable in conforming to the ideas
5504 II, 5. 5. 3 | absolute MS risk in the Maltese.~Prevalence of 39 and 21
5505 II, 5. 5. 3 | Piperidou HN, Heliopoulos IN, Maltezos ES, Milonas IA (2003): Epidemiological
5506 II, 5. 10. 5 | dextrose (1); wheat-based maltodextrins (1); glucose syrups based
5507 II, 7. 3. 5 | abandonment, and other forms of maltreatment (WHO, 2002).~ ~For all age
5508 III, 10. 5. 1 | Nursing 52(3): 328-339~Rogers MAM, Zaragoza-Lao E: Happiness
5509 III, 10. 3. 4 | effort. In order to remain a manageable enterprise, the scope of
5510 IV, 12. 10 | Darmstadt~Prog T, uve GmbH für Managementberatung Berlin~Nach a, Institut
5511 II, 5. 8. 7 | Collaborative Research Group.( Manca anno) International variation
5512 II, 5. 8. 7 | GJ, Sibille Y eds. ERS (Mancano le pagine)~ ~Fabbri LM,
5513 III, 10. 6. 1 | 163:1012–1017~Van Dijk J, Manchin R, Van Kesteren J, Hideg
5514 II, 5. 7. 7 | Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi
5515 IV, 11. 6. 3 | that by encouraging (or mandating) high income individuals
5516 II, 9. 1. 2 | Vigan C, Fevotte J, Kiel G, Mandereau L, for the Occupational
5517 III, 10. 2. 1 | survey: summary statistics. G’Mangia, Department of Health Information.~ ~
5518 II, 5. 3. 9 | Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I, and the EUROCARE-4
5519 II, 5. 2. 7 | Garside DB, Greenland P, Manheim LM, Dyer AR, Wang R, Lubitz
5520 II, 9. 2. 3 | time, related diseases are manifesting themselves in the childhood
5521 II, 5. 5. 3 | CC, Bergman P, Widhalm K, Manios Y, Breidenasse C, Kersting
5522 III, 10. 5. 1 | increases in a stronger mannner than the actual resident
5523 IV, 13. 6. 2 | appropriateness of facilities and manpower. The more the development
5524 II, 5. 12. 7 | Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois B,
5525 II, 5. 5. 3 | Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca
5526 IV, 12. 10 | professionals, institutions, manufactures, insurance funds, and patient
5527 -, 1 | collaborate by providing manuscripts with high-quality scientific
5528 II, 5. 5. 3 | Benassi G, Naccarato S, Manzaroli D (1987): Prevalence of
5529 II, 5. 8. 7 | Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz D,
5530 II, 9. 1. 2 | Siracusa. Epidemiol Prev. 2004 Mar-Apr;28(2):87-93.~Botto LD, Lisi
5531 II, 9. 3. 2 | S, Ancel PY, Marpeau L, Marchand L, Pierrat V, Larroque B,
5532 II, 5. 8. 7 | Lawson J., Duggleby W.,Marciniuk D., Rennie D., Stang M (
5533 III, 10. 3. 2 | of cyanide spill in Baia Mare, 2000; from pyrotechnic
5534 II, 5. 5. 3 | Granieri et al., 1989 (*) /Maremmani et al., 1991 (*) /~Beghi
5535 II, 5. 15. 1 | Charcot-Marie-Tooth disease, Marfan syndrome, Retinitis Pigmentosa,
5536 -, 1 | Belli, Antonella Calabrò, Marina D’Avanzo and Paola Marini
5537 III, 10. 4. 5 | resource base upon which marine-related economic and social activities
5538 II, 5. 5. 3 | disease in the Republic of San Marino. Neurology 37(10):1679-1682.~
5539 II, 5. 8. 7 | Cazzoletti L, Beccaria M, Marinoni A, Viegi G, de Marco R (
5540 II, 5. 5. 3 | psychiatry 55:181-184.~Lai BC, Marion SA, Teschke K, Tsui JK (
5541 I, 2. 2 | almost 550 billion euro. Maritime transport was by far the
5542 IV, 13. 5 | Population ageing is an aggregate mark of human success in improving
5543 II, 5. 4. 8 | S5-12.~ ~Jonsson PM (2000), Marke LA, Nystrom L, Wall S, Ostman
5544 II, 9. 3. 3 | Fouchard J, Gruet F, McManus T, Markert S, Sandfort T, et al (1994) :
5545 IV, 11. 1. 3 | shift from centralized to market-based mechanisms. Broadly, there
5546 IV, 12. 10 | exclusion from the labor market-will have access, and to tackle
5547 III, 10. 2. 1 | regulation within a global marketplace.~ ~It is not just new drug
5548 IV, 12. 4 | Byrne in 1999, succeeded by Markos Kyprianou in 2004 and Androulla
5549 IV, 12. 4 | nanotechnology, consumer products.~MARKT~Benefits of Internal market
5550 II, 9. 3. 2 | 22.~ ~Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V,
5551 II, 5. 6. 6 | Lock C, Allgar V, Jones K, Marples G, Chandler C, Dawson P (
5552 II, 5. 7. 3 | Obrador et al, 2002) and is marred with difficulties (Winkelmayer
5553 II, 9. 4. 5 | the fact that most women marry men who are older than themselves.
5554 III, 10. 3. 2 | Research Centre Management~MARS~Major Accident Reporting
5555 III, 10. 2. 1 | Enríquez L, Moreno-Moreno MJ, Martí A (2007): Genetics of obesity.
5556 II, 5. 5. 3 | Sarasqueta C, de Arce A, Poza JJ, Marti-Masso JF (2004): Prevalence of
5557 II, 5. 5. 3 | 208-210.~Benito-Léon J, Martín E, Vela L et al (1998):
5558 III, 10. 2. 1 | McVie JC, Maisonneuve P, Martin-Moreno JM, Newton Bishop J, Oleari
5559 III, 10. 4. 5 | Volume 68: 183-197.~ ~Martine Vrijheid (2000): Health
5560 III, 10. 2. 1 | Health Care 30:209–211.~ ~Martínez-Hernández A, Enríquez L, Moreno-Moreno
5561 -, 1 | Pietro Folino Gallo, Paola Di Martino, Donato Greco, Nata Menabde,
5562 II, 9. 5. 3 | activities. To demonstrate their masculinity, many boys want to be seen
5563 II, 5. 5. 3 | Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A (
5564 II, 6. 3. 4 | good respiratory hygiene, mask-wearing in healthcare settings during
5565 IV, 12. 10 | campaign. Co-operation with the mass-media and TV, Co-operation with
5566 II, 9. 3. 2 | maternités de l'Europe. Paris: Masson, 1866.~ ~Lin HC, Xirasagar
5567 II, 5. 5. 3 | there is still no European master-plan resulting from the consultation
5568 IV, 12. 10 | Germany fit for children”), masterminded by Federal Ministry of Family,
5569 III, 10. 2. 4 | Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DHY,
5570 II, 9. 1. 2 | E, Siffel C, Stoll C and Mastroiacovo P (2006): "Trends of Selected
5571 II, 9. 3. 2 | Epidémiologie de la mortalité maternelle en France, de 1996 à 2002 :
5572 II, 9. 3. 2 | Le Fort L (1866) : Des maternités de l'Europe. Paris: Masson,
5573 II, 5. 3. 9 | Grosclaude P, Hédelin G, Matsuda T, Moller H, Moller T, Verdecchia
5574 II, 5. 8. 7 | 117: 339S-345S.~ ~Viegi G, Mattelli G, Angino A, Scognamiglio
5575 III, 10. 2. 4 | 466-471.~ ~Hoffmann K., Mattheisen M, Dahm S, Nürnberg P, Roe
5576 II, 5. 2. 7 | P, Cesana G, Ferrario M, Mattiello A, Pilotto L, Sega R, Giampaoli
5577 II, 5. 11. 3 | the 1985–1995 period (L Mattila et al. 2001).~ ~Available
5578 III, 10. 4. 2 | Standards Agency~United Kingdom~Mattilsynet – Norwegian Food Safety
5579 III, 10. 2. 1 | H (2004): Svenska barns matvanor 2003 - resultat från enkätfrågor [
5580 II, 5. 5. 3 | Sutcliffe RL, Prior R, Mawby B, McQuillan WJ (1985):
5581 III, 10. 2. 1 | and food security aimed at maximizing the benefits for public
5582 IV, 11. 6. 2 | be annual out-of-pocket maximums, ranging from about €100
5583 II, 5. 9. 7 | Gesundheitsforschung Gesundheitsschutz. May-Jun;50(5-6):701-10~ ~Simpson
5584 II, 5. 5. 3 | Pritchard C, Baldwin D, Mayers A (2004). Changing patterns
5585 IV, 12. 3 | currently operating in 820 mayor companies across the EU
5586 III, 10. 5. 1 | with the main goal to allow mayors and other locally elected
5587 III, 10. 1. 3 | Switzerland.~Meusel D, Maywald U, Hach I, Kirch W (2005):
5588 II, 5. 4. 8 | Fenech FF, Junoussov Z, Mazovetsky A, Olchanski V., (1995)
5589 II, 5. 9. 7 | G, Cricelli C, Sessa E, Mazzaglia G, Canonica GW, Passalacqua
5590 II, 9. 3. 1 | Boyle, P. Robertson, C. Mazzeha, C. Keech. M. Hobbs, F.D.R.
5591 III, 10. 2. 4 | the one case (e.g., due to MC4R mutant and being resistant
5592 II, 5. 8. 7 | 130: 1129-1137.~ ~Rea H, McAuley S, Stewart A, Lamont C,
5593 II, 5. 8. 7 | 11: 695-702.~ ~Buist AS, McBurnie MA, Vollmer WM, Gillespie
5594 II, 5. 7. 7 | 72(1):92-9.~Stewart JH, McCredie MR, Williams SM (2006):
5595 II, 5. 9. 7 | www.hcjz.hr~ ~Wang Y, McCusker C (2006): Neonatal exposure
5596 II, 9. 1. 2 | 7.~Schaefer C, Garbis H, McElhatton P, Reuvers M, Robert E,
5597 II, 9. 3. 3 | 42.~Kangas I, Andersen B, McGarrigle CA, Østergaard L (2004):
5598 II, 5. 5. 1 | Kessler R, Nelson C, McGonagle K, Liu G (1996): Comorbidity
5599 II, 9. 3. 1 | practice, 62(6):973-6~ ~Lee H, McGovern K, Finkelstein JS & Smith
5600 II, 8. 2. 1 | Register and of census (McGrother et al, 2002). The UK Department
5601 II, 5. 5. 3 | e141.~Saha S, Chant D, McGrrath J (2007): A systematic review
5602 II, 5. 5. 3 | study. Mult Scler 7:111-117.~McGuigan C, McCarthy A, Quigley C,
5603 II, 5. 7. 7 | CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O (2006): Obesity
5604 II, 9. 1. 2 | 21, pp 363-369.~Macintosh MCM, Fleming KM, Bailey JA et
5605 III, 10. 3. 1 | no. 4, 371-8.~Lucas R, McMichael T, Smith W, Armstrong B (
5606 III, 10. 2. 1 | Yang H, Platt RW, Usher R, McNamara H, Joseph KS, Wen SW (2002):
5607 III, 10. 2. 1 | Fagerström K, Jarvis MJ, Kunze M, McNeill A, Ramström L (2003): European
5608 III, 10. 4. 2 | of some heavy metals, 3-MCPD and benzo(a)pyrene in foodstuffs;
5609 II, 5. 2. 7 | Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigo
5610 II, 5. 6. 6 | Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,
5611 II, 6. 3. 5 | Figure 6.5. Measles (MCV1) vaccine coverage.~ ~
5612 II, 5. 5. 3 | Multiple Sclerosis, Louise McVay. This report was actively
5613 III, 10. 2. 1 | S, La Vecchia C, Levi F, McVie JC, Maisonneuve P, Martin-Moreno
5614 II, 9. 5. 6 | who.int/hq/2000/who_msd_mdp_00.1.pdf~ ~Women’s Aid (
5615 II, 6. 3. 2 | Multi-drug resistant TB (MDR-TB) was present in 15–20% of
5616 II, 5. 5. 3 | forbid certain foods; make mealtime pleasant; get help when
5617 II, 8. 2. 1 | Holland A, Krahn G, Lennox N, Meaney J & Wehmeyer M (2005). Reducing
5618 II, 5. 5. 3 | without implementation is meaningless;~· involve children in designing
5619 II, 7. 4 | action);~· Time frame and measurability of intermediate outcomes
5620 III, 10. 4. 2 | poultry, turkey and pig meats~Antibiotic resistance of
5621 III, 10. 3. 4 | transport accidents involving mechanized modes of transport, including
5622 II, 5. 5. 3 | Ott A, Grobbee DE, van der Meche FG, Hofman A (1995): Prevalence
5623 IV, 13. 9 | MJ, Köhler LI, Blair ME, Mechtler R (2003): Child Health Indicators
5624 II, 5. 5. 2(24)| funding from the Fondation Médéric Alzheimer.~
5625 II, 5. 5.Int(18)| and non-Western countries.MedGenMed.6:49.~
5626 II, 9. 5. 6 | www.euro.who.int/document/mediacentre/fs0605e.pdf~ ~WHO (2007):
5627 II, 5. 8. 2 | neonatal ( P2 ~· mediastinal ( J9 ~· surgical (subcutaneous) ( T ~·
5628 IV, 11. 6. 5 | dynamics of international medical-care reform." Journal of Economics
5629 IV, 11. 1. 5 | publishes guidelines on numerous medical-related procedures ranging from
5630 II, 5. 5. 3 | disorders, how to prevent and medicate anorexia and bulimia. Therefore,
5631 I, 2. 10. 4(11)| barcodescanning op het optreden van medicatie toedienfouten”, Elsbeth
5632 II, 5. 5. 1 | information on prscribed medicin3es on DDD levels per patient.~ ~
5633 IV, 11. 1. 5 | to occur more often than medicine-related errors. When looking at
5634 IV, 11. 6. 5 | practice: effectiveness and medico-legal aspects." Annals of the
5635 IV, 11. 4 | Research in biotechnology~· Medico-technical research~ ~Psychological,
5636 II, 5. 11. 3 | available for dermatologists, medics and scientists. Moreover,
5637 II, 5. 5. 3 | Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de
5638 II, 5. 11. 3 | including mild cases)~Meding B, et al~ ~Swedish school
5639 II, 5. 11. 3 | 000 deaths) and low- and medium-resource countries (28 500 cases
5640 IV, 12. 10 | Zentrum für Qualität in der Medizin, ÄZQ), see www. ~ ~Environmental
5641 II, 5. 5. 3 | German MS Society’s report “Mehr Lebensqualität, Sympomatische
5642 III, 10. 5. 1 | Rural Affairs, UK.~Desai MA, Mehta S, Smith KR (2004): Indoor
5643 II, 9. 3. 3 | O (2001): Seksin trendit meillä ja naapureissa (in Finnish) (
5644 III, 10. 2. 1 | Lagerlof F, Lingstrom P, Mejare I, Norderam G, Norlund A,
5645 II, 5. 5. 3 | de Rijk MC, Grigoletto F, Melcon MO, Breteler MM, Maraganore
5646 II, 5. 12. 7 | D'Argenio P, Esposito D, Mele A, Ortolani G, Adamo B,
5647 II, 5. 5.Int(15)| A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies
5648 II, 8. 2. 1 | Cooper, S.-A. Morrison, J., Melville, C. Finlayson, J., Allan,
5649 IV, 12. 10 | lang=en). It enumerates 23 member-hospitals (18 from the major Athens
5650 IV, 13. 4 | strategic policy objective for Member-States and the European Union as
5651 II, 9. 3. 1 | intranuclear receptors and putative membrane receptors to regulate intracellular
5652 II, 5. 4. 8 | diabetes register. DARTS/MEMO Collaboration.BMJ. 1997
5653 IV, 12. 8 | Programme through specific memoranda of understanding, so that
5654 IV, 11. 6. 5 | the data show?" Milbank Memorial Fund Quarterly 62(4): 591-
5655 II, 5. 5. 3 | certain topics, excellent memories and being ‘eccentric’. These
5656 -, 1 | Martino, Donato Greco, Nata Menabde, Antoni Montserrat, Zsuzsanna
5657 II, 9. 5. 3 | health. Girls who reached menarche by the age of 11 are more
5658 II, 5. 5. 3 | 384.~De Sã J, Paulos A, Mendes H, et al (2006): The prevalence
5659 II, 5. 10. 7 | Feighery C, Janssen FW, Méndez E, Mothes T, Troncone R,
5660 II, 5. 8. 7 | S, Burney P, Mannino DM, Menezes AMN, Sullivan S, Lee TAL,
5661 I, 3. 4 | Liefbroer & H. Moors (2001), Meningen en opvattingen van de bevolking
5662 II, 4. 2 | increase since 1970 for menl (Figure 4.2.4). The regression
5663 III, 10. 1. 3 | and alcohol abuse. Bull Menninger Clin 58(2 Suppl A):A58-66.~
5664 II, 9. 3. 1 | in what may be considered menopause-related sequelae. There is a lack
5665 II, 9. 5. 6 | and women aged 15–44. J Mens Health Gender, 3: 139-151.~ ~
5666 IV, 12. 10 | Entwicklung und Chancen junger Menschen in sozialen Brennpunkten
5667 III, 10. 2. 1 | 18-79~Dietary-history~28~Mensink G B M et.al. (2004) Food
5668 II, 9. 3. 1 | the permanent cessation of menstruation resulting from the loss
5669 III, 10. 3. 4 | countries indicate that the mental-health aspects of flood-related
5670 II, 5. 5. 1 | Study of the Epidemiology of Mentl Disorders (ESEMeD). J Clin
5671 III, 10. 2. 1 | Euromonitor International, 2007). Meranwhile, in France, a product specific
5672 II, 9. 4. 7 | Longevity Centre-UK and The Merck Company Foundation (2006):
5673 II, 5. 4. 7 | Consortia have decided to merge into a common initiative, “
5674 IV, 12. 10 | made decisions on municipal merges, reducing the total number
5675 IV, 12. 10 | 000. This can be done by merging, for which there are incentives,
5676 II, 5. 5. 3 | Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff
5677 IV, 12. 10 | in Ireland, which could merit the criminalisation of their
5678 II, 5. 6. 6 | Hulsemann JL, Mittendorf T, Merkesdal S, Handelmann S, der Schulenburg
5679 II, 5. 7. 7 | Diez Roux AV, Chambless L, Merkin SS, Arnett D, Eigenbrodt
5680 IV, 11. 6. 5 | 3): 3-25.~ ~Mossialos E, Merkur S et al. (2006): Incentives
5681 II, 5. 5. 3 | 146.~Kotsopoulos IAW, van Merode T, Kessels FGH, et al (2002):
5682 III, 10. 2. 1 | Miller W, Wilbourne P (2002): Mesa Grande: a methodological
5683 III, 10. 2. 1 | 82:940–946.~ ~Moreno LA, Mesana MI, Fleta J, Ruiz JR, González-Gross
5684 II, 5. 12. 7 | Vanlemmens C, Mantion G, Messner M, Launois B, Samuel D,
5685 II, 5. 2. 6 | cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol
5686 III, 10. 5. 2 | compared to urban residents. A meta-review carried out in New Zealand (
5687 II, 5. 5. 3 | Schizophrenien – Ergebnisse von Metaanalysen zur Wirksamkeit. Psychiat
5688 II, 9. 5. 3 | body weight and their different metabolisms as related to alcohol dehydrogenase
5689 III, 10. 2. 4 | cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase
5690 II, 5. 3. 7 | introduced in the treatment of metastatic cancer and thus the cost
5691 I, 2. 7 | where taxes and square meter prices were much lower.
5692 II, 5. 4. 4 | square of the height in meters. The outcome categories
5693 II, 9. 5. 6 | Lifestyle Intervention or Metformin. The New England Journal
5694 II, 5. 9. 2 | PRIST, RAST, spirometry and methacoline challenge were performed.
5695 Key, Ap5. 0. 0 | methemoglobinemia~methicillin-resistant~methicillin-sensitive~microalbuminuria~microbiologists~
5696 III, 10. 2. 1 | remethylation of homocysteine to methionine. The demethylation of folate
5697 II, 6. 3. 2 | nosocomial pathogens are methycillin-sensitive Staphylococcus aureus (Figure
5698 II, 5. 14. 5 | health services. Although meticulous oral hygiene and appropriate
5699 II, 9. 1. 2 | Lowry RB, McDonnell R, Metneki J, Poetzsch S, Ritvanen
5700 II, 9. 3. 3 | 2001. Population Health Metrics 2:5~Kirby D, Laris BA, Rolleri
5701 I, 2. 7 | new reality which sees the metropolis take centre stage. Cities
5702 III, 10. 3. 4 | Danube and up to 14% for the Meuse catchment. Preliminary results
5703 IV, 11. 6. 5 | 7): 653-98.~ ~Dovey SM, Meyers DS et al. (2002): "A preliminary
5704 II, 5. 5. 1 | Odds Ratio for a score MH5<55 by a number of Variables.~ ~
5705 II, 9. 3. 1 | Mental Health Europe (MHE): ht l (Article online,
5706 II, 5. 5.Int | health21. An example is the “MHEDEA-2000”-project, which carried
5707 II, 8. 2. 1 | Health Gap Action Programme mhGAP – Scaling up care for mental,
5708 III, 10. 2. 1 | WPT, Jackson-Leach R, nì Mhurchu C, Kalamara E, Shayeghi
5709 III, 10. 5. 1 | rodents such as rats and mice that live in public parks
5710 I, 2. 10. 2 | nanoparticles, the status of micelles/capsule and the number of
5711 IV, 11. 6. 5 | Klavus J, Hakkinen U (1998): "Micro-level analysis of distributional
5712 III, 10. 4. 2 | outbreaks in the EU~ ~ ~Disease/micro-organism~Occurrence~Trend~Main human
5713 III, 10. 2. 1 | workplace (Katz et al, 2005).~ ~Micro-scale interventions are likely
5714 II, 5. 11. 3 | electron microscopy and x-ray microanalysis, Archives of Dermatological
5715 III, 10. 2. 4 | provide information at the microanatomical level by the use of immunohistochemistry
5716 II, 5. 6. 3 | by a low bone mass and a microarchitectural deterioration of bone tissue,
5717 II, 5. 9. FB | the reduced exposure to microbes seen in Europe in the last
5718 I, 2. 10. 1 | plants and livestock; soil microbiology), or for innovation in varieties
5719 III, 10. 2. 1 | Körpermaße der Bevölkerung 2005 [Microcensus - questions about health –
5720 IV, 11. 4 | theory~· Macroeconomics~· Microeconomics~· Health economic methods
5721 III, 10. 2. 1 | Office for Europe: Macro- and microenvironmental determinants of physical activity.
5722 III, 10. 5. 1 | recommended 24-h limit value of 50 microgram/m3.~ ~Swedish intervention
5723 II, 5. 10. 1 | protein (in the range of few micrograms) may trigger a severe allergic
5724 II, 5. 11. 3 | using scanning electron microscopy and x-ray microanalysis,
5725 II, 5. 4. 1 | vessels, nerves and heart. Microvascular complications (diabetic
5726 IV, 11. 1. 5 | Nevertheless, since the mid-1960s the quality of healthcare
5727 II, 4. 1 | expectancy trend varied from the mid-1970s, whilst trends in Norway
5728 III, 10. 3. 2 | the extended Directive by mid-2005.~ ~The current chemicals
5729 III, 10. 4. 1 | particles is foreseen by mid-2007. The proposal may include
5730 III, 10. 2. 1 | started to operate in the mid-80s, by 2002, almost all EU
5731 II, 9. 4. 1 | factors that shape youth and mid-life experience, such as social
5732 II, 6. 3. 4 | recognised as a global threat in mid-March 2003 in East Asia. By July
5733 II, 9. 1. 1 | date back at least to the mid-nineteenth century (Le Fort, 1866;
5734 III, 10. 5. 3 | points below the Stockholm mid-term target). This is the result
5735 II, 4. 3 | 2006): Healthy People 2010 Midcourse Review: Executive summary.
5736 II, 9. 4. 6 | older people, less young to middle-age, stable child / teen numbers)~ ~
5737 II, 5. 5. 3 | Aarseth JH, Myhr KM, Nyland H, Midgard R (2004): Multiple sclerosis
5738 II, 5. 11. 3 | East and industrialized Midlands and lower rates in Wales
5739 II, 9. 2. 3 | abused and neglected in its midst, it is also unable to take
5740 II, 5. 12. 7 | Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000): Permutation tests
5741 II, 5. 8. 3 | received care through the Upper Midwest Veterans’ Integrated Service
5742 III, 10. 2. 1 | the literature. Journal of Midwifery Womens Health 48:338–345.~ ~
5743 II, 5. 6. 6 | N, Jacobs AE, Kempen GI, Miedema HS, Tijhuis MA, de Haes
5744 III, 10. 3. 2 | Rüdiger, R, Ostermann, B, Mielke, H. (2005): Rückstände von
5745 III, 10. 2. 1 | Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau J, van der
5746 III, 10. 5. 2 | especially younger people migrate into urban areas, which
5747 III, 10. 3. 4 | drowning and of negative migration-related health effects~Source: adapted
5748 I, 3. 2 | Commission points out that migrations to EU-countries have been
5749 IV, 11. 6. 2 | unofficial fees or gifts (Mihai, 2003).~ ~It appears that
5750 III, 10. 2. 1 | Statistical Office (2006): Mikrozensus - Fragen zur Gesundheid –
5751 II, 5. 5. 3 | J Neurol Sci 103:29-36.~Milanov I, Georgiev D, Kmetska K,
5752 III, 10. 5. 1 | 97:559–569.~Milstead TM, Miles R, Röbbel N. (2006): Housing
5753 II, 9. 5. 3 | relationship and in every social milieu. Estimates on violence against
5754 III, 10. 3. 1 | opdracht van de Vlaamse Milieumaatschappij, MIRA, MIRA/2003/02, Vito.
5755 II, 9. 5. 6 | ÎSkolgrden, -vuxnas bilder -barns miljñÌ~ ~Michels KB (2006) : Birthweight
5756 III, 10. 3. 1 | Health 10(38),27-33.~Barns Miljö och Hälsa, (2005): Children’
5757 III, 10. 2. 1 | with age, beginning with milk-teeth, reaching a peak at puberty,
5758 IV, 12. 10 | 2007.~ ~Approximately € 2.5 mill. was in 2007 allocated to
5759 III, 10. 5. 1 | EllsWorth DS, Jonshen KH, Bonnie Millar HY (2007):~Temporal dynamics
5760 II, 5. 6. 6 | at the Start of the New Millenium. Report of a WHO Scientific
5761 II, 5. 10. 7 | 135-147.~ ~Brusic V, Millot M, Petrovsky N, Gendel SM,
5762 II, 9. 1. 2 | 33.~Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk
5763 II, 5. 5. 3 | Heliopoulos IN, Maltezos ES, Milonas IA (2003): Epidemiological
5764 II, 5. 8. 7 | Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz D, Toren K,
5765 II, 5. 5. 3 | Livingston Elsevier 671-681.~Minderhoud JM, Zwanniken CF (1994):
5766 II, 8. 2. 1 | disabilities in Europe. Mindful of these gaps in knowledge,
5767 II, 9. 2. 2 | rates.~ ~Children are not miniature adults, their needs and
5768 III, 10. 4. 3 | supply practice are the minimization of contamination of source
5769 I, 2. 10. 4(10)| Informe. Febrero 2006. Ministerio de Sanidad y Consumo, Madrid
5770 III, 10. 3. 2 | Nordrhein-Westfalen. Im Auftrag des Ministeriums für Umwelt und Naturschutz,
5771 III, 10. 4. 2 | Élelmiszer-biztonsági Hivatal~Hungary~Ministero della Salute~Italy~Pārtikas
5772 I, 2. 10. 4(20)| Confererence 13-15 June 2006, Minneapolis, Usa~
5773 II, 5. 6. 6 | arthritis in Rochester, Minnesota: a study of incidence, prevalence,
5774 II, 5. 6. 6 | Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis
5775 IV, 11. 6. 5 | role of Medicine: dream, mirage or nemesis? Oxford: Blackwell
5776 IV, 11. 6. 4 | emergency, neonatal/maternal, miscellanea) and a list of 54 outcome
5777 III, 10. 2. 1(12)| may miss some cases and misclassify a drug-related death as
5778 IV, 11. 1. 5 | lapses in treatment delivery, miscommunication, complications in payment
5779 II, 9. 3. 1 | older women, it is often misdiagnosed and under-treated leading
5780 II, 5. 4. 2 | dividends in reduction of human misery and in massive savings of
5781 II, 5. 5. 3 | Endziniene M, Pauza V, Miseviciene V (1997): Prevalence of
5782 III, 10. 2. 1 | is accurate and does not mislead the consumer.~ ~The Directive
5783 III, 10. 5. 3 | Theorell, 1990) and a mismatch of occupational efforts
5784 II, 9. 1. 2 | urethral opening in boys is misplaced, has a prevalence of a minimum
5785 II, 5. 1. 2 | and is worried that he may misread in case of little or even
5786 IV, 12. 8 | and conferences. Special missions were organised in each country
5787 III, 10. 4. 5 | causes dermatitis when it mistakenly penetrates a person's skin
5788 III, 10. 1. 1 | relapse in recovering alcohol misusers. Again, heavy drinking may
5789 III, 10. 5. 1 | living and that cannot be mitigated or removed by the individuals.
5790 II, 5. 5. 3 | blood-brain barrier constituents. Mitoxantrone is sometimes used for the
5791 II, 5. 6. 6 | 35:498-502~Hulsemann JL, Mittendorf T, Merkesdal S, Handelmann
5792 IV, 11. 6. 1 | characteristics (public-private mixes, technology implemented)
5793 II, 5. 6. 6 | 34-43~Brooks PM (1997): MJA Practice Essentials - Rheumatology.
5794 IV, 12. 10 | practice for foods products mkt to children is panned. Improving
5795 IV, 12. 10 | Main regulations adopted~MMain programmes on citizen empowerment~
5796 II, 9. 3. 1 | Massachusetts Male Ageing Study (MMAS). From this data source
5797 II, 9. 3. 2 | maternal death. Accurate MMRs require the inclusion of
5798 II, 5. 5. 3 | EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges
5799 IV, 11. 5. 5 | The success depends on the mobilisation of the European transplant
5800 IV, 12. 4 | agencies are generally able to mobilise a significant number of
5801 III, 10. 2. 4 | OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi
5802 IV, 12. 10 | combat work-related diseases (Modellprogramm zur Bekämpfung arbeitsbedingter
5803 II, 5. 5. 3 | study of the prodrome and moderating risk/resilience factors
5804 II, 9. 3. 1 | Avoidance of tobacco use and moderation in alcohol intake are obvious.
5805 III, 10. 1. 3 | detecting interactions and moderator effects. Psychol Bull 114(
5806 IV, 12. 10 | Modernization Act (Gesetz zur Modernisierung der gesetzlichen Krankenversicherung,
5807 III, 10. 1 | as confounders or effect modifiers (Figure 10.1.2) (Rosner,
5808 IV, 11. 6. 4 | that is, “a factor that modifies the effect of the exposure
5809 II, 5. 5. 3 | Darmstadt, pp 113-121.~Modrego Pardo PJ, Pina Latorre MA,
5810 III, 10. 1. 1 | energy expenditure are direct modulators of body weight. It is critically
5811 IV, 11. 6. 4 | Finance~Ministry of Health~MOH~None~Czech Republic~General
5812 II, 5. 8. 7 | 2006; 100: 1973-1980.~ ~Mohangoo AD, van der Linden MW, Schellevis
5813 IV, 12. 10 | and Social Solidarity (www.mohaw.gr) runs a dynamic campaign
5814 III, 10. 5. 1 | 2007): Health effects of mold in children. Pediatric Clinics
5815 III, 10. 4. 5 | 0.3 tonnes per capita in Moldova to 18 tonnes per capita
5816 II, 5. 1. 1 | lamina propria or large molecula. On the other hand, late
5817 II, 5. 5. 3 | Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM (
5818 II, 5. 5. 3 | Leclercq C, Kafatos A, Molnar D, Marcos A, Castillo M,
5819 II, 5. 8. 7 | Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. (2004):
5820 II, 5. 10. 5 | Lupin and products thereof~- Moluscs and products thereof~Directive
5821 II, 9. 5. 1 | is only beginning to gain momentum. Western societies typically
5822 II, 9. 3. 1 | Maternal mortality rate~MOMS~European Concerted Action
5823 II, 5. 8. 7 | Siafakas NM eds. Eur Respir Mon, Monograph 38, 2006; 11:
5824 II, 5. 5. 3 | Update on Multiple Sclerosis. Monduzzi Editore, Bologna, pp 253-
5825 II, 5. 5. 3 | Govoni V, Tola MR, Paolino E, Monetti VC, De Bastiani P (1991):
5826 II, 5. 2. 3 | and “hard” margarine to mono- and poly-unsaturated oils
5827 II, 9. 4. 3 | assumed to be either in monogamous relationships or relatively
5828 III, 10. 2. 4 | Rare Diseases). These diseases are monogenic and have a low frequency
5829 I, 2. 7 | Economics.~ ~The large-scale monographic exhibition of the work of
5830 II, 5. 5. 3 | National Cancer Institute Monographs 19:205-268.~Ebers (1998).
5831 III, 10. 4. 2 | polyacrylamide to release free monomeric acrylamide is reported to
5832 II, 5. 5. 3 | infections including infectious mononucleosis, and lifestyle factors also
5833 IV, 11. 6. 2 | administrative costs because of the monopsony purchaser and a universal
5834 II, 5. 8. 7 | de la Roza C, Morera J, Montemayor T, Gobartt E, Martin A,
5835 II, 5. 2. 6 | Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor HL (1966).
5836 II, 5. 5. 3 | Geneve.~Zivadinov R, Iona L, Monti-Bragadin L, et al (2003): The use
5837 -, 1 | Greco, Nata Menabde, Antoni Montserrat, Zsuzsanna Jakab, Arun Nanda,
5838 III, 10. 2. 1 | 1265–1271.~ ~Jotangia D, Moody A, Stamatakis E, Wardle
5839 III, 10. 1. 3 | Kroutil LA, Roland EJ, Moore-Gurrera M (1997): Issues in the
5840 I, 3. 4 | Henkens, A. Liefbroer & H. Moors (2001), Meningen en opvattingen
5841 II, 5. 5. 3 | Spain. J Neurol 244:182-185.~Mor u T, eaManceau E, Lucas
5842 III, 10. 2. 5 | 96(3):377-82~Madigan S, Moran G, Schuengel C (2007): Unresolved
5843 II, 5. 5. 3 | 0 per 1000 and lifetime morbid risk 7.2 per 1000, respectively.
5844 II, 5. 6. 6 | Utrecht, NIVEL. Basisrapport: Morbiditeit in de huisartspraktijk~ ~
5845 III, 10. 2. 1 | Fernandes T, Mourão I, Moreira P, Rosado V (2004): Prevalence
5846 III, 10. 2. 1 | Serra-Majem L, Foz-Sala M, Moreno-Esteban B, for the Grupo Colaborativo
5847 III, 10. 2. 1 | Martínez-Hernández A, Enríquez L, Moreno-Moreno MJ, Martí A (2007): Genetics
5848 II, 5. 8. 7 | Miravitlles M, de la Roza C, Morera J, Montemayor T, Gobartt
5849 III, 10. 2. 1 | Jefferson T, Lushey C, Morleo M, Stokes E, Sumnall H,
5850 II, 5. 7. 7 | screening based on spot morning urine samples to detect
5851 II, 5. 5. 3 | Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T,
5852 III, 10. 2. 1 | substances (codeine, slow-release morphine, diamorphine (heroin) etc.),
5853 II, 5. 5. 3 | Birchwood M, Juckel G, Morrirson A, Vázquèz-Barquero JL,
5854 II, 9. 3. 2 | 2006): Epidémiologie de la mortalité maternelle en France, de
5855 II, 9. 3. 1 | Czech Republic for females. Mortalities in the recent accession
5856 I, 2. 11 | Sauto Arce R, Tsolova S, Mortensen J (2005): The impact of
5857 II, 5. 11. 7 | Kay J, Gawkrodger DJ, Mortimer MJ et al (1994): The prevalence
5858 II, 5. 6. 6 | Lane and Philip N Sambrook) Mosby-Elsevier; Section C, Chapter 1.~Zollman
5859 II, 5. 3. 2 | esmo.org/resources/surveys/mosesII_survey/~ ~A global comparison
5860 IV, 11. 6. 3 | in Thomson, Foubister and Mossiaos 2008).~ ~The extent of progressiveness
5861 I, 2. 7 | continue to be one of the most-debated challenges of human settlements.
5862 II, 5. 5. 3 | Multiple sclerosis in Móstoles, central Spain. Acta Neurol
5863 III, 10. 2. 5 | comparative European data on early mother-child interaction.~ ~
5864 II, 5. 10. 7 | C, Janssen FW, Méndez E, Mothes T, Troncone R, Wieser H (
5865 III, 10. 2. 5 | levels of albumin;~- reduced motility and gastro-intestinal blood
5866 IV, 12. 10 | January 2008 that focuses on motivating families in Denmark with
5867 II, 9. 3. 1 | compared to women, underlying motivations have not received much attention
5868 II, 7. 3. 4 | pedestrians, cyclists and motorcyclists) account for at least 40%
5869 IV, 12. 10 | cigarette packages, signs at motorways indicating potential dangers
5870 III, 10. 6. 2 | be influenced mainly by moulding public opinion and by taking
5871 III, 10. 4. 2 | 2006). The Role of High Mountains in the Global Transport
5872 III, 10. 2. 1 | Spanish).~ ~Monteiro CA, Moura EC, Conde WL, Popkin BM (
5873 III, 10. 2. 1 | Padez C, Fernandes T, Mourão I, Moreira P, Rosado V (
5874 II, 5. 5. 3 | 297-309.~LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M (
5875 III, 10. 2. 1 | vibrating floss and on-the-go mouth-freshening strips.~Consumer expectations
5876 III, 10. 2. 1 | dental floss, dental care, mouthwashes, fresheners, toothbrushes,
5877 II, 5. 12. 7 | OV, McQuillan GM, Gao F, Moyer LA,~Kaslow RA, Margolis
5878 III, 10. 2. 1 | A, Agoston H, Balázs A, Mozsáry E, Vitrai J, Hermann D,
5879 II, 5. 2. 6 | Factor Intervention Trial (MRFIT). JAMA 256: 2823-2828.~Turnbull
5880 III, 10. 4. 2 | exposure that is used in MRL-setting is the International Estimate
5881 III, 10. 2. 4 | Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H,
5882 IV, 11. 6. 2 | medical saving accounts (MSAs) (though these do not currently
5883 II, 8. 2. 3 | 31(6):409-46.~ ~Johansson MSK, Arlinger SD (2003): Prevalence
5884 II, 5. 3. 2 | the EU-27 Member States (MSs) have national cancer registration
5885 III, 10. 4. 1 | JRC~Joint Research Centre~MTFR~Maximal Technical Feasible
5886 IV, 11. 1. 4 | for health care has been much-debated in particular because it
5887 II, 5. 8. 2 | NOS ( J4 · simple and mucopurulent ( J4 ~· tracheitis ( J4 ~·
5888 II, 5. 6. 6 | Neuhaus JM, Ettinger WH, Mueller WH (1990): Body fat distribution
5889 II, 5. 8. 7 | Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL (
5890 IV, 12. 10 | gesundheitliche Prävention, IFGP Münster~Working conditions act (
5891 II, 5. 5. 3 | Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH,
5892 III, 10. 3. 1 | Lagarde F, Mäkeläinen I, Muirhead C, Oberaigner W, Pershagen
5893 II, 9. 3. 3 | Cousins G, Donnelly C, Mulcahy F, Conroy R (2006): The
5894 III, 10. 2. 1 | Keinan-Boker L, Peeters PH, Mulligan AA, Navarro C, Slimani N,
5895 III, 10. 4. 3 | integrated manner. Several multi- and bilateral agreements
5896 III, 10. 4. 1 | Europe. Clearly, asthma has a multi-causal background with many factors
5897 III, 10. 1 | contribution means consideration of multi-causality and interaction in order
5898 II, 5. 9. FB | purpose, large and adequate multi-centric clinical studies are required.
5899 III, 10. 2. 1 | Mortality among drug users12~ ~A multi-country study found that mortality
5900 II, 9. 5. 1 | Gender-specific health is multi-determined and includes many modifiable
5901 III, 10. 5. 3 | action plans~- promoting multi-dimensional, multi-professional European
5902 II, 5. 5. 3 | There is evidence for a multi-factorial pathogenesis including genetic
5903 III, 10. 2. 1 | subsectors of oral care with multi-functional products combining toothpaste
5904 II, 5. 5. 3 | the elderly may be needed.~Multi-national studies should be performed
5905 III, 10. 5. 1 | psychological effects of crowding. Multi-occupation dwellings and flats, particularly
5906 III, 10. 4. 2 | detecting 30 to 40 compounds in multi-residue methods in several runs
5907 II, 9. 3. 3 | be followed through via a multi-sectorial approach and the active
5908 III, 10. 2. 1 | influence through standardised multi-session programmes which can be
5909 IV, 11. 3. 2 | dispense the least-cost multi-sourced product. However, this policy
5910 III, 10. 6. 1 | all Member States was a multi-stage, random (probability) sampling
5911 III, 10. 3. 2 | SAICM was developed by a multi-stakeholder Preparatory Committee, co-convened
5912 II, 9. 2. 7 | Perspective On Family Structures: Multi-State Early Life Tables Using
5913 II, 6. 3. 7 | patients develop severe multi-system disease and up to 15% of
5914 IV, 11. 1. 6 | contracts in the context of multi-task agency relationships (Robinson
5915 III, 10. 2. 1 | questionnaires are now available as “multidomain” instruments to collect
5916 II, 5. 2. 4 | CVD incidence.~CVD has a multifactor aetiology, which means that
5917 II, 5. 5. 3 | Consensus Group~PML~Progressive Multifocal Leukoencephalopathy~PP-MS~
5918 III, 10. 2. 1 | education programme using multimedia. Limited evidence is found
5919 III, 10. 2. 4 | metabolizer genotypes by multiplex polymerase chain reaction,
5920 III, 10. 3. 1 | exposure and smoking is multiplicative (for the general population
5921 IV, 11. 1. 5 | information technology, a multiplicity of programmes and guidelines
5922 IV, 11. 5. 1 | the quality of life, have multiplied the indications of these
5923 II, 5. 7. 1 | where it acts as a risk multiplier (Sarnak et al. 2003). Furthermore,
5924 I, 2. 7 | city promotes the idea of multipurpose spaces which convey the
5925 II, 5. 2. 5 | individuals at high-risk in a multisector cooperation and action.~
5926 II, 5. 5. 3 | 2001 (*)~Sweden~Adults ~Multisource medical register review~
5927 II, 5. 9. 5 | geographically dispersed multispecialty group practices and independent
5928 II, 5. 11. 4 | to treat. A wide range of multisystem dermatological diseases
5929 I, 2. 7 | Los Angeles, Mexico City, Mumbai, Sao Paulo, Shanghai and
5930 II, 5. 5. 3 | De La Puente E, Lopez de Munain A, Sarasqueta C, de Arce
5931 III, 10. 2. 1 | considered increasingly mundane by consumers, the burgeoning
5932 II, 5. 5. 3 | 63(10):892-909.~Lange W, Munk-Jørgensen P, Bertelsen A, Schürmann
5933 III, 10. 2. 1 | homicides (4 in 10 of all murders)~- 17,000 deaths from road
5934 II, 5. 5. 3 | of multiple sclerosis in Mures County, Romania. Rom J Neurol
5935 II, 9. 1. 2 | referral of babies with a heart murmur for early echography. Severe
5936 III, 10. 2. 1 | Asciak RP, Dalmas M, Gatt M, Muscat NA, Calleja N (2003): The
5937 II, 9. 2. 3 | engage in weight-gaining and muscle-enhancing activities (WHO/HSBC 2004).
5938 I, 2. 5 | safety issues because of muscular-skeletal disorders. Higher skilled
5939 III, 10. 3. 1 | cardiovascular, respiratory and musculo-skeletal systems and to depression.
5940 II, 5. 6. 6 | 1998): The gender gap in musculoskeletal-related long-term sickness absence
5941 II, 6. 3. 7 | wild rabbits, hares and muskrats, as well as some domestic
5942 II, 5. 10. 7 | Hoffmann-Sommergruber K, Lidholm J, Mustakov T, Oude Elberink JNG, Pumphrey
5943 II, 5. 10. 5 | Celery and products thereof~- Mustard and products thereof~- Sesame
5944 III, 10. 2. 4 | case (e.g., due to MC4R mutant and being resistant to any
5945 | MY
5946 II, 9. 2. 3 | multidrug-resistant (MDR) strains of Mycobacteria, reinjection and/or reactivation,
5947 II, 5. 5. 3 | Blom BH, Skeidsvoll H, Mykletun A (2000): Prevalence, classification,
5948 II, 5. 2. 6 | routine introduction of new myocite damage markers (troponins),
5949 II, 5. 15.Acr | Association Française contre les Myopathies~COMP~Committee of Orphan
5950 II, 5. 5. 3 | 66:182-186.~Grønlie SA, Myrvoll E, Hansen G, et al (2000):
5951 III, 10. 1. 3 | files/20080109$110739$fil$mZ8UVQv2wQFShMRF6cuT.pdf]~EEA (European Environment
5952 II, 9. 3. 3 | Seksin trendit meillä ja naapureissa (in Finnish) (Trends in
5953 II, 5. 6. 6 | 1991): Een Nationale Studie Naar Ziekten en Verrichtingen
5954 II, 5. 5. 3 | Granieri E, Benassi G, Naccarato S, Manzaroli D (1987): Prevalence
5955 II, 5. 11. 3 | population in North America (NACDG), Contact Dermatitis, 2008,
5956 III, 10. 3. 2 | Lebensmitteln und verbraucher nachen Produkten.~ ~European Chemical
5957 IV, 12. 10 | Schutz vor Gewalttaten und Nachstellungen, Gewaltschutzgesetz, GewSchG);
5958 III, 10. 4. 2 | antimicrobial resistance nad food borne outbreaks in
5959 IV, 12. 10 | Aktionsforum Diabetes Mellitus, NAFDM, www e, since 2004): targets
5960 III, 10. 4. 2 | food~In domestic kitchens~Nagao & Sugimura, 2000~Acrylamide~
5961 III, 10. 5. 1 | Stadtentwicklung (2004): Nahverkehrsplan des Landes Berlin. Fortschreibung
5962 II, 5. 11. 1 | other structures including nails, hair, blood vessels, nerves,
5963 II, 5. 12. 7 | Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F,
5964 II, 9. 5. 1 | more comprehensive and less naïve understanding of what engenders
5965 II, 5. 6. 6 | Thiesce A, Listrat V, Jacob L, Nakache JP, Gabriel KR, Lequesne
5966 III, 10. 4. 2 | R, Kato, S, Sasaki, S, Nakajima, S, Uno, A, Saijo, Y, Sata,
5967 II, 5. 11. 3 | 130.~T Nakada, M Iijima, H Nakayama, HI Maibach, Role of ear
5968 III, 10. 4. 2 | Yoshimura, Y, Kishi, R, Nakazawa, H.(2004). Perfluorooctane
5969 II, 5. 5. 3 | ahead of print].~Byerly MJ, Nakonezny PA, Lescouflair E (2007):
5970 II, 5. 11. 7 | Svensson A, Diepgen Th, Naldi L, Coenraads PJ, Elsner
5971 II, 9. 3. 3 | administering about 2000 nameless questionnaires to boys and
5972 II, 7.Acr | Lost~ ~Project/ Programme names used: ADRISK, ANAMORT, ANEC,
5973 II, 5. 10. 7 | 32: 373-378.~Løvik M and Namork N (2004): The Norwegian
5974 I, 2. 10. 2 | number of dimensions in the Nan orange). Engineered nanoparticles
5975 II, 9. 3. 3 | 1998 and 2003.~Wellings K, Nanchahak K, Macdowall W, McManus
5976 II, 5. 6. 6 | rheumatology, 1st ed. (Edited by Nancy E Lane and Philip N Sambrook)
5977 -, 1 | Montserrat, Zsuzsanna Jakab, Arun Nanda, Walter Ricciardi, Stefania
5978 I, 2. 5 | biological effects, such as nano particles, may result in
5979 III, 10. 4. 3 | water are appearing, e.g. nano-materials or residues of human- and
5980 Key, Ap5. 0. 0 | nano-particles~nano-technology~naphthalenes~nasal~necrosis~
5981 I, 2. 10. 2 | semiconductors (also named nanocrystals), which under stimulation
5982 I, 2. 11 | potential of materials at the nanolevel. Science, vol. 311, 622-
5983 I, 2. 10. 2 | defining a substance as a nanomaterial. But some aspects are known
5984 I, 2. 10. 2 | reporting scheme for engineered nanomaterials in general and only nine
5985 I, 2. 10. 2 | particular in cancer imaging:~- Nanorods: nanoparticles with 1- 100
5986 I, 2. 10. 2 | droplet diameters in the nanoscale; surfactants maintain their
5987 I, 2. 10. 2 | skincare;~- Quantum dots: Nanosized semiconductors (also named
5988 I, 2. 11 | Oberdörster G. et al., (2005): Nanotoxicology: An emerging discipline
5989 I, 2. 10. 2 | tissue-binding capacity. Carbon nanotubes, of large use, with a cylinder
5990 IV, 12. 10 | Deutschland 2005-2010" (NAP, national action plan “Germany
5991 II, 5. 5. 3 | J 331:60-61.~Beilmann A, Napa A, Soot A, et al (1999):
5992 IV, 12. 10 | inequalities.~htt e/~documents/NAPinclusionreportPDF~.pdf .~ ~The Senior Officials
5993 II, 5. 12. 7 | infections in children in Naples, Italy. Public Health 103:
5994 III, 10. 3. 2 | Biphenyls~PCN~Polychlorinated napthalenes~PFS~Perflourinated substances~
5995 II, 9. 3. 3 | J, Weston R, Peersman G, Napuli IZ, Interventions for encouraging
5996 IV, 12. 10 | substance abuse consists of Narcotics Law (Betäubungsmittelgesetz),
5997 IV, 12. 10 | substance abuse~ high~ ~2007: Narkoen ud af byen~http da~Sexual
5998 II, 5. 10. 3 | in the latter (Løvik and Narmok, 2004). In adults, main
5999 II, 6. 3. 2 | still represented by older narrow-spectrum antibiotics, whilst newer
6000 III, 10. 2. 1 | between boys and girls is narrower than expected, especially
